Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00276172 · ClinicalTrials.gov registry record · Phase 3
Open-Label Natalizumab Safety Extension Study
A Phase 3 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,615
- Enrollment target
NCT00276172: Completed Phase 3 study, sponsored by Biogen.
NCT00276172 is a Phase 3 study that has completed, run by Biogen. The registered enrollment target is 1,615 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (109% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00276172, a Phase 3 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,615 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the safety and the immunogenicity of extended treatment with natalizumab when administered at a dose of 300 mg intravenously (IV) to subjects with multiple sclerosis (MS) who have completed natalizumab Studies C-1801, C-1802, or C-1803.
Interventions
- DRUG Natalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,615 participants |
| Start Date | 2003-12 |
| Est. Completion | 2006-01 |
| Phase | Phase 3 |
What the finished NCT00276172 record still lists
NCT00276172 is an interventional study that assigns participants to a tested intervention. Its 1,615 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (109% higher).
The record links to 0 conditions, and to 1 intervention - of which Natalizumab is the first listed.
NCT00276172 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00276172 about?
NCT00276172 is a clinical study titled "Open-Label Natalizumab Safety Extension Study". The primary objective of this study is to determine the safety and the immunogenicity of extended treatment with natalizumab when administered at a dose of 300 mg intravenously (IV) to subjects with multiple sclerosis (MS) who have completed natalizumab Studies C-1801, C-1802, or C-1803.
What is the current status of trial NCT00276172?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,615 participants. The study started on 2003-12. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00276172?
The interventions under investigation include: Natalizumab (DRUG).
Who is sponsoring clinical trial NCT00276172?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00276172's enrollment target sits among peer trials
1,615 142nd of 2000 higher than 1,859 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06959524 · 1,616 participants · NA
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions
- NCT06271590 · 1,605 participants · NA
MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels
- NCT00646022 · 1,600 participants
Natural History of Familial Carcinoid Tumor
- NCT03109197 · 1,600 participants
Sudden Unexplained Death in Childhood (SUDC) Registry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia